CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer

Cure­Vac today announced that Dr. Franz-Wern­er Haas, pre­vi­ous­ly act­ing Chief Exec­u­tive Offi­cer and Chief Oper­at­ing Offi­cer (COO), has been appoint­ed Chief Exec­u­tive Offi­cer (CEO).

Before Dr. Haas joined Cure­Vac in June 2012, he worked as Vice Pres­i­dent Oper­a­tions and Chief Com­pli­ance Offi­cer of SYGNIS Phar­ma AG, where he was respon­si­ble for the exe­cu­tion of M&A and cap­i­tal mar­ket trans­ac­tions. Dr. Haas start­ed his pro­fes­sion­al career as an assis­tant to the man­age­ment of a pri­vate­ly-held hold­ing com­pa­ny before assum­ing sev­er­al man­age­ment posi­tions in the life sci­ences indus­try, includ­ing Vice Pres­i­dent and Gen­er­al Coun­sel of LION bio­science and Gen­er­al Coun­sel of Sirona Den­tal Sys­tems. He stud­ied law at the Uni­ver­si­ty of Saar­brueck­en, Catholic Uni­ver­si­ty of Leu­ven and the Uni­ver­si­ty of Edinburgh.

In addi­tion to the appoint­ment of Dr. Haas as CEO, Cure­Vac has announced that Igor Splaws­ki, Ph.D., joins the exec­u­tive team as Chief Sci­en­tif­ic Offi­cer with imme­di­ate effect. In this role, he will be respon­si­ble for lead­ing CureVac’s mRNA biol­o­gy research. Dr. Splaws­ki comes to Cure­Vac from the Novar­tis Insti­tutes for Bio­Med­ical Research (NIBR), where he served for two years as Exec­u­tive Direc­tor and Site Head of the NIBR Bio­log­ics Cen­ter in Cam­bridge, Mass. Dr. Splaws­ki was an Assis­tant Pro­fes­sor at Har­vard Med­ical School from 2005 to 2008 and has a Ph.D. in human genet­ics from